The Landscape of Biomarker Testing Coverage in the U.S.

February 28, 2022

Biomarker testing is becoming increasingly important for cancer care because it connects the right patient, to the right treatment, at the right time, however insurance coverage of testing varies widely. This study, that examines administrative claims data to understand the premium impact of expanding biomarker testing coverage in four markets: commercial self-insured large group, small group, individual, and Medicaid, found a small potential impact on insurance premiums as a result of higher utilization of biomarker testing.